Reports Q1 revenue $188.8M vs $25.3M last year. “The positive readout from our first Phase 3 trial, the first ever for a PROTAC, is a tremendous accomplishment and one which we are very proud of,” said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas (ARVN). “Our conviction is high that vepdegestrant can be highly competitive as a monotherapy treatment option for metastatic breast cancer in the second-line, ESR1 mutant setting. We are on track to submit a regulatory filing with health authorities, which we believe could result in the first ever approval of a PROTAC and an exciting opportunity to bring a novel treatment to patients with ESR1 mutant advanced metastatic breast cancer.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas Showcases Promising Preclinical Data at AACR
- Arvinas reports data from preclinical combination studies of ARV-393
- Arvinas price target lowered to $21 from $65 at Truist
- Promising Phase 1 Results and Favorable Safety Profile of ARV-102 Support Buy Rating for Arvinas Holding Company
- Arvinas Holding’s Innovative Approach and Promising Data Justify Buy Rating